Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: Published experience

Clinical and Experimental Rheumatology

Volumn 27, Issue 3, 2009, Pages 446-451

  Schimmel, Elizabeth K ^a   Yazici, Yusuf ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Biologic therapy; Cholesterol; Lipids; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; ATHEROGENESIS; ATHEROGENIC INDEX; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; HUMANS; LIPIDS; RISK FACTORS;

EID: 67651183984     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. VAN DOORNUM S, MC GOLL G, WICKS IP: Accerlerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 2002; 46: 862-873
2. ALLANORE Y: Cardiovascular mortality in patients with inflammatory rheumatic disorders. Joint Bone Spine 2007; 74: 120-122
3. BOERS M, NURMOHAMED MT, DOELMAN CJ et al.: Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-845
4. HURT-CAMEJO E, PAREDES S, MASANA L et al.: Elevated levels of small, low-density lipoproteins with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this artherogenic profile. Arthritis Rheum 2001; 44: 2761-2767
5. GROWER SA, COUPAL L, XIAO-PING H: Identifying adults at increased risk of coronary disease. JAMA 1995; 274: 801-806
6. LEE YH, CHOI SJ, JI JD et al.: Lipoprotein (a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000; 19: 324-325 (Pubitemid 30612569)
7. SITUNAYAKE RD, KITAS G: Dyslipidaemia and rheumatoid arthritis. Ann Rheum Dis 1997; 56: 366-368
8. PARK YB, AHN CW, CHOI HK et al.: Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46: 1714-1719
9. KUMEDA Y, INABA M, GOTO H et al.: Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1489-1497
10. GONZALEZ-JUANATEY C, LLORCA J, TESTA A, REVUELTA J, GARCIA-PORRUA C, GONZALEZ-GAY MA: Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthiritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407-413
11. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594-1602
12. SAAG KG, TENG GG, PATKAR NM et al.: ACR recommendations for the use of non-biologic and biologic therapies in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-784
13. CAUZA E, CAUZA K, HANUSCH-ENSERER U et al.: Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002; 114: 1004-1007
14. DAHLQVIST S, ENGSTRAND S, BERGLIN E et al.: Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006; 35: 107-111
15. KIORTSIS D, MAVRIDIS A, FILIPPATOS T et al.: Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006; 33: 921-923
16. SAIKI O, TAKAO R, NARUSE Y et al.: Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 2007; 34: 1997-2004.
17. NISHIMOTO N, YOSHIZAKI K, MAEDA K et al.: Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis: phase I/II clinical study. J Rheumatol 2003; 30: 1426-1435
18. ALLANORE Y, KAHAN A, SELLAM J et al.: Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clinica Chimica Acta 2006; 365: 143-148 (Pubitemid 43196430)
19. IRACE C, MANCUSO G, FIASCHI E et al.: Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 17: 113-118
20. PETERS M, VAN HALM V, WOLBINK G et al.: Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 958-961 (Pubitemid 46999801)
21. POPA C, VAN DEN HOOGEN F, RADSTAKE T et al.: Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-1507 (Pubitemid 350032660)
22. SPANAKIS E, SIDIROPOULOS P, PAPADAKIS J et al.: Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33: 2440-2446
23. TAM K, TOMLINSON B, CHU T et al.: Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1495-1498
24. VIS M, NURMOHAMED M, WOLBINK G et al.: Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-255 (Pubitemid 40209122)
25. SERIOLO B, PAOLINO S, SULLI A et al.: Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006; 1069: 414-419 (Pubitemid 43989884)
26. SOUBRIER M, JOUANEL P, MATHIEU S et al.: Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2007; 20: 1-3
27. SERIOLO B, PAOLINO S, FERRONE C, CUTOLO M: Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol 2007; 26: 1799-1800
28. POPA C, NETEA MG, RADSTAKE T et al.: Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-305
29. GONZALEZ-JUANATEY C, LLORCA J, SANCHEZ ANDRADE A et al.: Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-312
30. NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-1769 (Pubitemid 38725087)
31. JACOBSSON L, TURRESSON C, GULFE A et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218
32. GONZALEZ-JUANATEY C, LLORCA J, TESTA A et al.: Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407-413
33. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-86
34. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 373-379
35. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-316 (Pubitemid 351659139)
36. GONZALEZ-GAY MA, LLORCA J, GARCIA-UNZUETA MT et al.: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 596-603.
37. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, BERIA A et al.: Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1644-1646
38. MAINI R, TAYLOR P, SZECHINSKI J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-2829